Overview

Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Status:
Withdrawn
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Astex Pharmaceuticals
Astex Pharmaceuticals, Inc.